Avalo Therapeutics, Inc.
AVTX Nasdaq
SEC CIK 1534120
Follow Avalo Therapeutics
Weekly email: filings, results
Net income
−$18.9M
+38.1% vs same quarter last year
EPS, diluted
−$0.34
+84.5% vs same quarter last year
Operating cash flow
−$11.5M
+29.5% vs same quarter last year
Operating income
−$23.4M
−21.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $59K | −$78.3M |
| FY24 | $441K | −$35.1M |
| FY23 | $1.9M | −$31.5M |
| FY22 | $18.1M | −$41.7M |
| FY21 | $5.4M | −$84.4M |
| FY20 | $6.7M | −$63.5M |
| FY19 | $6.8M | −$16.1M |
| FY18 | $7M | −$40.1M |
| FY17 | $27.8M | $11.9M |
| FY16 | $1.2M | −$16.5M |
| FY15 | $0 | −$10.5M |
| FY14 | - | −$16.1M |
| FY13 | - | −$13M |
| FY12 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | −123601.7% | −132642.4% |
| FY24 | - | −15535.6% | −7965.8% |
| FY23 | 33.3% | −1421.6% | −1639.5% |
| FY22 | 81% | −207.4% | −230.8% |
| FY21 | 72.4% | −1521.6% | −1563.1% |
| FY20 | 95.5% | −1087.4% | −947.9% |
| FY19 | - | −239.1% | −238.1% |
| FY18 | 53.6% | −503.4% | −569.9% |
| FY17 | 97.7% | 49.9% | 42.7% |
| FY16 | 100% | −1394.6% | −1428.6% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$26.8M |
| FY21 | −$71M |
| FY20 | −$40.6M |
| FY19 | −$19.4M |
| FY18 | −$3.7M |
| FY17 | $12.6M |
| FY16 | −$14.6M |
| FY15 | −$10.2M |
| FY14 | −$15.5M |
| FY13 | −$11.5M |
| FY12 | - |
- Avalo Therapeutics
- Healthcare median
Show the numbers
| Year | Avalo Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −132642.4% | −30.6% |
| FY24 | −7965.8% | −47% |
| FY23 | −1639.5% | −58% |
| FY22 | −230.8% | −80.4% |
| FY21 | −1563.1% | −71.8% |
| FY20 | −947.9% | −62.2% |
| FY19 | −238.1% | −46.2% |
| FY18 | −569.9% | −49.6% |
| FY17 | 42.7% | −45.9% |
| FY16 | −1428.6% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |